- Report
- March 2024
- 190 Pages
Global
From €3259EUR$3,374USD£2,787GBP
€3621EUR$3,749USD£3,097GBP
- Report
- May 2023
- 120 Pages
Global
From €5747EUR$5,950USD£4,915GBP
- Report
- February 2024
- 200 Pages
Global
From €4830EUR$5,000USD£4,130GBP
- Report
- October 2023
- 150 Pages
Global
From €4685EUR$4,850USD£4,006GBP
- Report
- May 2024
- 184 Pages
Global
From €5265EUR$5,450USD£4,502GBP
- Report
- December 2023
- 297 Pages
Global
€4825EUR$4,995USD£4,126GBP
- Report
- July 2023
- 179 Pages
Global
From €4347EUR$4,500USD£3,717GBP
- Report
- May 2023
- 85 Pages
United States
From €5747EUR$5,950USD£4,915GBP
- Report
- October 2023
- 107 Pages
North America
From €2029EUR$2,100USD£1,735GBP
€2898EUR$3,000USD£2,478GBP
- Report
- March 2024
- 190 Pages
Global
From €3259EUR$3,374USD£2,787GBP
€3621EUR$3,749USD£3,097GBP
- Report
- December 2023
- 200 Pages
Global
From €4830EUR$5,000USD£4,130GBP
- Report
- December 2023
- 200 Pages
Global
From €4830EUR$5,000USD£4,130GBP
- Report
- March 2024
- 134 Pages
Global
From €7679EUR$7,950USD£6,567GBP
- Report
- October 2023
- 145 Pages
Global
From €3043EUR$3,150USD£2,602GBP
- Report
- February 2024
- 111 Pages
Global
From €4588EUR$4,750USD£3,923GBP
- Report
- December 2023
- 140 Pages
Global
From €4299EUR$4,450USD£3,676GBP
- Report
- August 2023
- 145 Pages
Global
From €3043EUR$3,150USD£2,602GBP
- Report
- August 2021
- 452 Pages
Global
From €4782EUR$4,950USD£4,089GBP
- Report
- September 2021
- 262 Pages
Global
From €3622EUR$3,750USD£3,097GBP
- Report
- April 2023
- 145 Pages
United States
From €2029EUR$2,100USD£1,735GBP
€2898EUR$3,000USD£2,478GBP
The Intravenous Immunoglobulin (IVIG) market is a subset of the biotechnology industry that focuses on the production and distribution of immunoglobulin products. IVIG is a blood product derived from the pooled plasma of healthy donors, and is used to treat a variety of conditions, including autoimmune diseases, infections, and immunodeficiencies. IVIG is also used in the prevention of certain infections in immunocompromised patients.
IVIG is produced by a number of companies, including CSL Behring, Grifols, Kedrion, Octapharma, and Biotest. These companies are involved in the production, distribution, and marketing of IVIG products. They also provide support services such as patient education, reimbursement assistance, and clinical trial support. Additionally, some companies are involved in the development of new IVIG products, such as recombinant immunoglobulins and monoclonal antibodies. Show Less Read more